Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -4.67% 51.00 50.00 52.00 53.50 50.50 53.50 568,576 14:48:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.0 -17.4 -6.7 - 133

Angle PLC Director/PDMR Shareholding

19/07/2022 10:00am

UK Regulatory (RNS & others)


Angle (LSE:AGL)
Historical Stock Chart


From Jun 2022 to Dec 2022

Click Here for more Angle Charts.

TIDMAGL

RNS Number : 9552S

Angle PLC

19 July 2022

19 July 2022

For immediate release

ANGLE plc ("the Company")

Director/ PDMR shareholding

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, following the Results of Capital Raise announcement on 15 July 2022, it has been notified by Andrew Newland, Chief Executive Officer, and Ian Griffiths, CFO, of the following share purchases.

 
 1.     Details of the person discharging managerial responsibilities/person 
         closely associated 
 (a)    Name                                     Andrew Newland 
       ---------------------------------------  ------------------------------------ 
 2.     Reason for the notification 
       ----------------------------------------------------------------------------- 
 (a)    Position/status                          Chief Executive Officer 
       ---------------------------------------  ------------------------------------ 
 (b)    Initial notification/                    Initial notification 
         Amendment 
       ---------------------------------------  ------------------------------------ 
 3.     Details of the issuer 
       ----------------------------------------------------------------------------- 
 (a)    Name                                     ANGLE plc 
       ---------------------------------------  ------------------------------------ 
 (b)    LEI                                      213800BY11K6W3NMS374 
       ---------------------------------------  ------------------------------------ 
 4.     Details of the transaction(s): section to be repeated 
         for (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions 
         have been conducted 
       ----------------------------------------------------------------------------- 
 (a)    Description                              Ordinary shares of 10 pence each 
         of the Financial 
         Instrument 
       ---------------------------------------  ------------------------------------ 
 (b)    Identification                           ISIN: GB0034330679 
         code of the Financial 
         Instrument 
       ---------------------------------------  ------------------------------------ 
 (c)    Nature of the                            Acquisition of Ordinary Shares 
         transaction 
       ---------------------------------------  ------------------------------------ 
 (d)    Price(s) and                             Price(s)           Volume(s) 
         volume(s) 
                                                -----------------  ----------------- 
   GBP0.80                                                          125,000 
  ---------------------------------------------------------------  ----------------- 
 
 (e)    Aggregated information                   As above 
       ---------------------------------------  ------------------------------------ 
 (f)    Date of the                              19 July 2022 
         transaction 
       ---------------------------------------  ------------------------------------ 
 (g)    Place of the                             Off market 
         transaction 
       ---------------------------------------  ------------------------------------ 
 
 
 2.     Details of the person discharging managerial responsibilities/person 
         closely associated 
 (a)    Name                                      Ian Griffiths 
       ----------------------------------------  ------------------------------------ 
 2.     Reason for the notification 
       ------------------------------------------------------------------------------ 
 (a)    Position/status                           Finance Director 
       ----------------------------------------  ------------------------------------ 
 (b)    Initial notification/                     Initial notification 
         Amendment 
       ----------------------------------------  ------------------------------------ 
 3.     Details of the issuer 
       ------------------------------------------------------------------------------ 
 (a)    Name                                      ANGLE plc 
       ----------------------------------------  ------------------------------------ 
 (b)    LEI                                       213800BY11K6W3NMS374 
       ----------------------------------------  ------------------------------------ 
 4.     Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions 
         have been conducted 
       ------------------------------------------------------------------------------ 
 (a)    Description of                            Ordinary shares of 10 pence each 
         the Financial 
         Instrument 
       ----------------------------------------  ------------------------------------ 
 (b)    Identification                            ISIN: GB0034330679 
         code of the Financial 
         Instrument 
       ----------------------------------------  ------------------------------------ 
 (c)    Nature of the                             Acquisition of Ordinary Shares 
         transaction 
       ----------------------------------------  ------------------------------------ 
 (d)    Price(s) and                              Price(s)           Volume(s) 
         volume(s) 
                                                 -----------------  ----------------- 
   GBP0.80                                                           37,500 
  ----------------------------------------------------------------  ----------------- 
 
 (e)    Aggregated information                    As above 
       ----------------------------------------  ------------------------------------ 
 (f)    Date of the transaction                   19 July 2022 
       ----------------------------------------  ------------------------------------ 
 (g)    Place of the                              Off Market 
         transaction 
       ----------------------------------------  ------------------------------------ 
 

For further information:

 
 ANGLE plc                                                   +44 (0) 1483 343434 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
  Andrew Holder, Head of Investor Relations 
 Berenberg (NOMAD & Joint Broker) 
  Toby Flaux, Ciaran Walsh, Milo Bonser, Thomas Graham         +44 (0) 20 3207 7800 
 
   Jefferies (Joint Broker) 
   Max Jones, Thomas Bective, Michael Gold, Shaam Vora         +44 (0) 20 7029 8000 
 
 FTI Consulting 
  Simon Conway, Ciara Martin                                   +44 (0) 203 727 1000 
  Matthew Ventimiglia (US)                                     +1 (212) 850 5624 
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) . Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world-leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology known as the Parsortix(R) system and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's Parsortix(R) system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to harvest intact circulating cancer cells from blood.

Intended use

The Parsortix(R) PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K(2) EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

The Parsortix system enables a liquid biopsy (a simple blood test) to be used to provide the circulating metastatic breast cancer cells to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs harvested from the system enable a complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis as well as cytological and morphological examination and may provide comparable analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

The Parsortix technology is the subject of 26 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.

In the United States, the Parsortix(R) PC1 system has received a Class II Classification from FDA for use with metastatic breast cancer patients. FDA clearance is seen as the global gold standard. ANGLE's Parsortix system is the first ever FDA cleared system for harvesting CTCs for subsequent analysis. ANGLE has applied the IVD CE Mark to the same system for the same intended use in Europe.

ANGLE has also completed two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation and a 200 patient clinical verification study has now completed enrolment.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEAD(TM) platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 63 peer-reviewed publications and numerous publicly available posters from 31 independent cancer centres, available on our website.

ANGLE has established clinical services laboratories in the UK and the United States to accelerate commercialisation of the Parsortix system and act as demonstrators to support product development. The laboratories offer services globally to pharmaceutical and biotech customers for use of Parsortix in cancer drug trials and, once the laboratories are accredited and tests validated, will provide laboratory developed tests (LDTs) for patient management.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHVKLBFLDLBBBE

(END) Dow Jones Newswires

July 19, 2022 05:00 ET (09:00 GMT)

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart
Your Recent History
LSE
AGL
Angle
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221203 23:32:58